Q3 2019 Earnings Call
Ladies and gentlemen, thank you for standing by I Am Adriano page I call operator, welcome and thank you for joining high Jens Q3, 2019 earnings conference call with [laughter] at this time, all participants are in listen only mode.
I said this call is being recorded at high genomic tests will be made available on their internet site.
Please press the star key followed by zero for operator system.
Also joining us today its phebe little from IR team. Please note that this call is being webcast live and will be archived on the Investor Relations section of our website at <unk> Dot Com a copy of the press release is also available in the same section.
Before we begin let me cover Safe Harbor statement the discussions responses to your questions on this call reflect management's view as of today Thursday October 30, Onest 2019, we'll be making statements and providing response to your questions that state or intentions beliefs expectations or predictions of the future. He's constitute forward looking statements for the purpose.
The safe Harbor provisions.
Payments involve risks and uncertainties that could cause actual results to differ materially from those projected.
Hi, Jim disclaims any intention or obligation revise any forward looking statements for more information. Please refer to our filings with the U.S. Securities and Exchange Commission.
On behalf of my colleagues, India Executive Committee and or Oh.
Our employees I would like to Franco for exceptional comfort is from an impact on catching.
He has played a cure wouldn't reaching a true success during their life sciences on diagnostic.
Yeah, Jim is a company like <unk> and they both great adventures inside them, some health care and I wish for all the best in his future endeavors.
On these core to do or don't want I would like to review our performance for the fourth quarter our outlook for the rest of the sure and provide some perspective on these people go trends is a collection.
We have a committed team taking actions to ensure growth and create value of catching we are focusing on the most attractive areas of our portfolio.
I was the first point net sales for the first quarter of two falls on them I tend to well for younger than $82.7 million and the rose 3% constant extends right see our this was below our outlook for about 4% to 5% <unk> growth due to weaker than expected said.
In China.
Did decline went beyond just continuation of did you read their ngs system joint venture out that you announced in July .
No the fact or waiting on growth was the decline in companion diagnostic revenues, which were down 57% <unk> are in the quarter.
At the same time adjusting earnings per share were 50 cents.
<unk> as well on a reported basis and she's was Oh, hi hand or by wear out.
Second we continue to make good progress we thought were sometime between sorry <unk>.
As an example ourselves to life science customers Rose, 7% <unk> are in the fourth quarter led by your 10 farm outs, then put some <unk> pharma increase.
I can give me a and applied testing customer class or so short improving trends compared to earlier in nitrogen.
Were up 6% <unk> against the third quarter of two fold gonna minutes.
Molecular diagnostic centers declined 2% CR due primarily to the challenges in China and north so decline in companion diagnostic revenues.
We have a very strong compared to 29% <unk> growth in the fourth quarter over 18 for quantity film, but we still anticipate head FY <unk>.
Our growth rate for two fall Gonna nights.
And as you saw we know where we view this week, we have expended the market for comps you feel blessed to have developing countries into fight against you'd be.
What's your feeling plus was just added to the catalog of to grow more drug facilities GDS global supply and you should see from stopped TB that is the largest provider to the public sector have doubled your which show recommended she'd be medicines diagnosing I'm not directory supplies.
GDS makes to test available to enroll resource regions, we support from centralized labs.
Listing opens a new channel to reach countries, we are high she'd be pretty finance in particular.
Yes, we're kinda agenda has no direct commercial prisons.
And notably as you have seen we've announced on October sit front, a 15 year strategic partnership with you leave me not unions U.S.K. any court decision, making.
Joining forces with Illumina will enable us to get to broaden their use of ins, yes into clinical laboratories.
At the same time, we have decided to discontinue our engineers in three months you brookman programs.
He sees very concrete transmission, although I will commitment to make strong portfolio decision and invest where caojing makes or read a difference.
You won't here to note that we continue to set Virginia reader Ngs system, which is designed for small talk it you didn't find is and continue to support customers around the world.
We also want to continue driving the growth of our Universal Ngs solutions, including the <unk> line of products and by doing promising solutions that talk to date. The vast majority although were Ngs says.
I spoke to reorientation about we're into your strategy, we announced in early October pretax charge into fourth quarter of two falls on a nights.
The charge was $276.8 million, you know pitching resorts more than 70% invoke noncash items and was 89 cents per share after taxes.
And that's one last point, we have updated our outlook for food you know.
For the first nine months of the your we now expect net sales growth of about 4% see off for the full year and she's going pass through the probably your outlook for 5% to 6% growth.
We also revised our outlook for <unk> as to about 1.42 free to one point $44 per share.
<unk> again going pay up to why we're probably your outlook for about 142 to one fault you for <unk>.
Going to the fourth quarter, we expect net sales growth of about 3% C. R and adjusted EPS of about 45 to 46 cents.
This takes into account that we are now expecting lower revenues from companion diagnostic gold you brought them and project in the fourth quarter overnight you know.
Given that we have stopped I were Ngs seems Freeman development programs. We know we now have to stop our Ngs based companion diagnostics activities.
But we aren't going to progress you'd be transition. These programs to really mean that sequences and then we'd be a timing effect at this time.
Remember that I were ends yes.
I would have companion diagnostic activities are made those two main activities PCR based we shall remain extremely strong and ngs that we are going to no progressively transfer to our eating that partnership.
Another factor for the outlook is our decision to take a.
More cautious view on the plan says ramp up for the Cat, Yes, Stott diagnostics Syndromic testing system for now.
The very positive foreign she's but we have no reached 800 cumulative placements for cancer diagnostics.
We hot $11 million of says for the first nine month from 19 against I will target for the boat $15 million for this period.
What I would like to highlight here is that do you smoke cautious approach has also driven by the fact that we algae leading to launch about where millions I did you spend that in Europe , and the gastrointestinal find it into your ways to the first half of two falls on Mtwenty initially those to fund as well due to cold.
In the last quarter of 19, we all know dealing with him and he says an impact on some customer placement steel I would achievement of 800 placement ideally positioned to tell you didn't for the coming years and we remain convinced about the GE, France is shown in customer value.
Oh felt by <unk> diagnostic.
With this I would like no to hand over to oral thank you.
And on to those off you in Europe , and good morning, Philadelphians, Yes, I would like to know if you all financials for the sought caught off and first nine months I'll see you.
Net sales to the so called off 2019, well see another 82.7 billion U.S. dollar us and just supposed to see per cent increase at constant exchange rate.
Sales calls when other parts. It pays are supposed to 1% and just supposed to do to address comments. He had been about two percentage points such broad line <unk> outlook.
For the first nine month of 2019 net sales were 1.11 billion U.S. dollar increase of 4% at constant exchange with.
Another part that phases says corpus of uncles and due to see percentage points of currency headwind.
The trends for this first nine months of CEO sure. That's adjusted gross margin at 70.7% in the first nine month of 2019 compared to 71.1% in 2018, which remains at a strong level, especially as we all supporting multiple new product launches.
Adjusted operating income margin, both 27 point it per cent compared to 27.9% <unk> a year period.
Well the first nine months of 29 to <unk> adjusted operating income was largely unchanged at 283.2 million U.S. dollar compared to $282.9 million into Sip It in 2018.
This was cited in an adjusted operating income margin of 25.4% for the first three quarters of 29 teen compared to 25 point. It was said the Sip <unk>.
For the first nine months of 2019 adjusted earnings per share we're at 98 cents at sea.
Adverse currency headwinds that uses but two cents to 96 cents I never thought that business.
In terms of cash flow, we saw a decline in operating cash flow for the first nine months of 29 team to $221.4 million compared to $249 billion for the same period in 2018.
As long as a key factors about cash payments for biotechs payments in part to sell tax audit for prior years, which will quote for the past.
Investment property plant and equipment were also higher the first nine months of 29 team well I think to $86.4 million from $72.3 million <unk> 2018.
Moving onto the balance sheet, it's and that's the first nine months of 29 team or leverage ratio stood at 1.7 times net debt to EBITDA up I'm, a slightly higher than is the same period of 2018.
You saw a decline and liquidity to $799 million films.
Nine on a 21 billion U.S. dollar.
Probably your p. or yet it's the same time net debt increased to $963 million from $848 million the same period of 28.
This primarily reflects the inflow of cash forms a business. That's the best proceeds from the issuance of $5.9 billion of new cashed out the convertible notes against the arc Ftwelve about $430 million fully payment for 29 didn't catch a convertible notes the first caught off this year as well as investment the building.
I would like to provide some more details on the restructuring charges, such a being tick primarily into sort caught up.
Along with our new partnership is Illumina to drive clinical use of LNG as we decided to discontinue development of new Ngs instruments.
Also in doctoral, though we announced plans to shift or production organizations into a regional structural and although to a decision to expense the scope of activities at archives business.
So this is sun belt in Poland, and the Philippines.
Besides has become increasingly essential in providing scalable professional services to support the company and our customers.
Because I don't see these initiatives, we are taking a pre tax restructuring charge off to another $76.8 million operating results for the sort of caught off 29.
It's a majority of says shops, as well said, 73% involves noncash items related to the decision to discontinue ngs instrument development.
We currently anticipate an additional protects the structure shots or football, it's supposed to $70 million or bought four or five cents per share after texas to be taken in the fourth caught off 2019 related to this measure and for a charge in the single digit billion dollar wage in 2020.
I would like to know reviews sales results based on our two product categories and also our customers.
Life Science and molecular diagnostics.
Fifth of consumables and the related revenues was 5% see out to see another $42 million. So I'd call. It though and it represented 89% of sits just wasn't aligned with the trend for the first nine months of 2019 with sales up 5% see up to $990 million and all.
So representing 89% of fifth.
Instrument sales on the other had faced a challenging comparison, the so called off 2018, and die and 11% see up $41 million.
Does that 11% of total sales.
We also continued to see encroaching placements off some normal <unk> system in Europe .
I'll have 10 S is once it's fully integrated PCR systems and be Villa decide as per our agreement on the full acquisitions by mid 2020.
As another point, we have also seen a sterilization and also I pod to revenues for instrument services. After they had been over the last few quarters instrument sales in life science declined as modest single digit see our way it but were supported by over 432 mother to placements often you version.
I'll circle back to connect Sop and processing instrument, it's up you launched earlier this year.
The first nine months of 2019 instrument sales were down by two cents C or to $1.20 $3 million.
Represented 11% of told cells, while underlying sales excluded suck parts and service revenue was up 2% <unk>.
In the molecular diagnostics customer class sales declined 2% see out to one that at 83 million U.S. dollar the sought caught off 2019 and it appears that that 48% of total sales <unk>.
It would be so low single digit see I cant in consumer boats and the related revenues, but also the dollar did you see our dropping instrument sets.
As to be mentioned earlier said subsequent to feel ought to be Tesco, 18% see out go up so it's simple since he off for the first nine months of CEO .
However, we saw 37% see I decline for the quarter companion diagnostic co development revenues, which were also down 14% see up so it is $3 million for the first nine month offices here.
We have noted before that's itself I bought a lot Todd and face a challenging comparison and 29 team whose have done that makes 34% CEOC will in 20 <unk>.
As an additional point, we had ongoing solid placements are kinda symphonies system and other did you see I grew up in a related consumer goods and on track to reach our goal for more than 2005 for not to limit cumulative placements at the end of 20 910 compared to 2003 and that.
That's enough twisted tea 18.
For the first nine months of 2019 molecular diagnostic sales were up 4% C R and like I presented 48% of tools.
It's a life sciences, we saw an acceleration in the performance compared to the first off of 29 team resets rising 7% see the soft caught off 29 to $1.90 $9 million compared to same period in 2018, and the epicenter, 52% of told says.
So higher contributions in particular in Europe , and the growth markets like Turkey, Italy, and Spain, just customer class also benefited.
From high Associates from all ends on Metics product line.
That's in the academia applied testing customer Clos were up 6% C or led by high single digit see our growth in consumer goods set more than offset a single digit see our decline in instrument sales.
Sales of our asset technologies for use in PCR testing short improving trends after a weakness the first half of 29 team.
We saw improving trends in a number of western European countries in particular, France, Italy, and the United Kingdom, and also solid trends and talkie. However, we saw another quarter of declining mid single digit see ourselves in Germany, which we believe are tied to vika customer sentiment about funding.
For the stuff nine months of 2019 sits in this region were up five cents he up to $341 billion and drill so do you want to send off towards sales.
Sits in the Americas regions were up 4% see up to $1.90 $2 million into sought caught up and represented 50% of says.
The U.S. delivered growth in live this region and it was at its best supported by mid single digit CEOC and in Brazil, and kinda, though.
For the first nine months of 2019 Medical school at the same for persistency appears reaching $5.2 million field and providing 49% of towards sales.
Shied up was that offset mid single digit see I grew up in Japan, and Australia and double digit see our sales gains in India and South Korea.
Thank you all.
I would like to give you some more details on our performance in China. There is no doubt that I'd tell you again, we are clearly disappointed by the third quarter, ensuring that but at the same time, we'd be that that market remains a key source of growth and potential growth for a company.
As we have mentioned servicing these concrete declined 24% see ought to $26 million into first quarter of my team from 35 million starting to same period of to focus on energy.
Let me try to explain what's happening in China.
As we mentioned in our pre announcement earlier. This month, we saw a weaker than expected trends in China from some distributors as you remember.
Significant thought about where says in China uncle <unk> from competitors from commercial partners. We estimate that these created a headwind of about 20 percentage points on the results for this quarter.
Do you slowed down in ordering pattern from some of our well just bbten came as they were seeing a slowdown in payments coming in from their own customers. The host Pete doors and go laboratories.
We also faced a headwind of about 11 percentage points human resource for the first quarter overnight units as a result of roughly $4 million says in 18 from did just continued China Ngs joint venture.
At the same time, we saw about eight put some grow from the rest of our portfolio in China, which he is way too about two filled somebody to diagnose CIC and about one for life science customers.
As I said before we believe it the fundamentals in these markets are good but we are seeing good mode. They slowed down in demand and have accordingly, adjusted supply capacity with our distributors.
Some of you know I wasn't my Sarofim, starting that recently and I've been working for some years in these countries as well.
We are now we decided to.
Implement.
Growing measures of distributors control and distributors monitoring in these markets.
We see de slowed down that's a temporary issue and it came after more than 20% see our growth in the first half of this year, our current expectation for the fourth quarter is an improvement in China.
And now let me just goes down you orientation of our next generation sequencing strategy in light of the new strategic partner sheep, we didn't even though.
First of all you then she is I will says are the key growth driver for carriage and I know we are reaffirming I will go in for more than one under then $80 million for a full year two phenomena.
We now have four key components of the spot for you.
First.
The majority of sales come from my where you know sort of Ngs solution, which include present any t. called consuming board and gene partners that can be used with any kind of sequencer.
These combined is very nicely, we do see couldn't large component, which involves our bio informatics solution for use with the vast amounts of data being generated.
This as you remember include the CFC portfolio for secondary analyses and I were expanding suites of solution for fish, everybody sees under the caption clinique or inside Brent.
It also includes the Omicsoft <unk> that provides a mutual makes data management solution.
And end of one we just got your Gen quite at the start of nitrogen to strengthen the capabilities in order to dark anchor allergy decisions. Your book and as you remember, we said that enough wonder mounted for roughly 1 million themselves.
The felt confident I don't know involves the partnership with Illumina.
And that's where less confident we will I said before continued to commercialize the genes, we don't ngs system for targets, either smaller partners and Cds as a complimentary to do you mean that partners.
I know a few world on Oh geez exciting.
Strategic partnership, we see leaving them I strongly believe that he sees one of the too few example, when two key leaders on the musket come together on the very growing musket de ngs for clinical application.
We want to leverage our deep expertize in companion diagnostic development and that with top position in sample processing and by your informatics.
This will be combine wheezy, let me know excellence in Ngs platform technology.
They are growing installed base of platform around the world and sequencing development firepower.
I saw the specific.
We have gained the rights to develop and global globally commercialize companion diagnostic and I read it keeps on Illuminas my seek diagnostic.
And next six diagnostic system for the future. We also have rights to use their future diagnostic sequences.
We are also exploring opportunities to do you blow up on musket companion diagnostic based on the let me not through site on coverage that's phase and he says you know we'd be key <unk> immuno oncology market.
We will seek regulatory approvals for our own partners on do you mean assist them and then combine those assays with I were pre analogy course solution and bio informatics.
Any short focus will be on solution for oncology, including companion diagnostic.
But that's you have seen we have secured.
Rights to explore Ivy <expletive> Teets for those are areas, such as infectious disease auto immune diseases, calgene hereditary disease and inflammatory issues.
Now onto slide 12.
We show clearly on how are those two companies portfolios Opco means you know very nice synergistic way.
In terms of revenue streams, we want to increase the number of could you broke not just for companion diagnostics based on Ngs.
Got you engine, we received milestone and also payments for this work from I will pharmaceutical and biotech problem that.
You. Let me now also is eligible to receive milestone payment from those project.
We are also planning to generate sales for the IBT kits for which we getting the regulatory approval in Europe , the U.S. and those are markets worldwide.
Got you agenda, we booked doses.
Yeah, Let me know interim we'd be at IGI board for us.
Standout single digit percentage royalty payment.
And that's what I sports, we have made the mode that once I am thrilled and technology access payment to discount but.
We will continue to book says forward I was sample technologies, including in three months and from my where by doing for metric solution for all those customers. Just like we are currently doing we that way you never sold.
ER Ngs solution and now we're back to oral.
Yeah.
Thank you tell you I would like to know if you outlook for 29 team.
As noted earlier, we have updated or outlook for total net sales go up approximately 4% see Oh, we have updated outlook for adjusted diluted EPS to 140 suite to $144 spare shale or a chunk constant exchange rates since it's a higher and off the previous winch of 142 to 140.
<unk> dollars.
As for currencies based on the weights as of October . So at this 2019 in terms of net sales. We expect it cannot see AD spend of about three percentage points on a pause at extra weights.
Adjusted EPS for the full year, they expect a currency headwind of about three to four cents per share.
For the fourth quarter outlook is for the toward that says scope of about 3% see a.
This includes lower web just for companion diagnostic co development projects and to create a headwind of about two to three percentage points.
Adjusted diluted EPS is expected to be about 45 to 46 cents per share and at constant exchange threats.
In terms of currency impact for the fourth quarter <unk> based on rates as of October . So I'll. Just 2019, you expect headwinds of about two percentage points on that said school at about one cents on adjusted EPS was that I would like had to add back to you.
Thank you are not once again and thanks, all for your attention before we move to the a question and answer session I'd like to summarize what we just described we saw at all.
First of all the weaker than expected saves reserves into first quarter up 19, well due to reduced sales in China and volatility in our companion diagnostic.
Those challenges overshadowed beta trends in the life science and all the areas of our portfolio.
But I would like to highlight again that I were adjusted earnings per share elsewhere at the high end of our outlook, which to me proves again the way, we clearly might not our financials seconds. We have a committee leadership team in place that he's focusing resources on the most attractive areas.
Well put forth.
I remain convinced that catch and has attractive fundamental growth opportunities and we are all I'd tell you had been determined to emerge as a stronger and more differentiated leader.
Further the strategic partnership we didn't even though he's a signal well by well compete shouldn't up or I, both our ngs portfolio as we expand our present in these key growth market as I said before it's also a concrete example, although I will commitment to relocate portfolio, where we can clearly be and become.
Im leaders.
And does it last point, we have updated that were 40 year Nitin outlook based on the reserved for the first quarter for the net sales growth of 4% C. R and adjusted EPS of 143 to $144 per share I see our again.
He is also include our outlook for net sales growth of 3% C. R and not just U.S. or 45 to 46 cents see are for the fourth quarter. I believe that do you see is a very realistic ambition for the fourth quarter and for the year.
With that I'd like to hand back to John <unk> and European retail for the Q and efficient. Thank you very much.
Operator.
Thank you ladies and gentlemen at this time, we will begin to answer.
To answer session anyone who wishes ask a question May press star, one I'm not catch town telephone.
I wish to withdraw your question you May press star followed by chance.
Sure we can accommodate as many people if possible. Please limit yourselves to only one question and if necessary one follow up your microphone will also be needed. After you finish asking the question.
Anyone who has a question May press star one at this time when on that for the first question.
Well go first to Steve Michelle.
Research.
[laughter] Hi, good morning, and good afternoon for those are there. Thanks for the time and Terry Thanks for joining welcome to the call.
I have two topics I'd like to raise one is just a little bit of bridging if you don't mind Roland I Wonder if you could just isolate the impact of the revised companion diagnostics outlook and the termination of the Ngs development efforts and talking about what those mean in the aggregate at the EBITDA line.
Respectively, I should they impact said another way should those in total and change the way, we think about the L. R. P for the EBITDA line and then one for Terry I Wonder if you could talk about.
Your views to the extent they might be different from what we've seen historically on investments in new technology.
The company has historically been or at least over the last few years somewhat acquisitive.
New technologies and diagnostics.
I'm not actually sort of next up so can you talk a little bit about how do you think about investing in new technologies is the hurdle rate at the bar, there going higher and how should we think about prospectively investing and commercialization on those technologies is the ramp on spend there any different than it might have been historically excellent.
[noise].
At this time, we're not hearing anything like Speaker. Please go ahead, sorry, I was you would I was talking so nice it do you Steve I do it again [laughter] and.
And again I think.
It's it's very fair to say is that Oh, we have seen expecting a nice margin develop into so caught up at all to the for the fourth quarter and Oh. So we would expect it for 2020 and that is clearly partially driven by the affect US you were alluding to Steve a companion diagnostic, particularly on the Ngs side.
Is a.
However, there was a a low margin business on the PC outside it's actually a good or the margin driven business for us. So if you do is a calculations in terms of our guidance for the fourth quarter backwards you kill it can sees that EBIT margin for the sought quota for the fourth quarter when adjusted basis has to be nicely.
Other 30% growth a 40% percentage wed and also looking under 2020, we expect he a nice expansion going forward. So it's a mix is clearly shifting or somebody profitable for us nothing that is good news for us.
Thank you all on Steve's to your second question on and your investment if I go to question because he twice a bit noisy on a new investment in new technologies for the future I really believe that I'd just point, we used a significant investment that we have done over the last two to three years, we have ideally a pause.
Got you tend to be extremely competitive.
For me, it's very clear we are to meet kept company and and and when do we are mid cap, we need to focus on where we can take between number one and number three for position on the market. It's not about mimicking what do you want goes out doing.
And so if you look at the recent investment as we don't said before Pneumovax, which is ramping up quite a a nicely got yes. That's the same and do you mean that partnership just for the molecular diagnostic portfolio. If you can see though the coming launching the second half of two falls on a twin killed by where digital PCR in lifestyle.
Since we have everything in hand at this moment.
To compete and to be successful and to me now it's a matter of execution.
And so in terms of reallocation of resources I, we see much more resources did you could teach you first in development fueling those platform with the appropriate menu.
Instead of the marketing or did you see making sure that we have the feet on the grown to push those sort of shown on the market and on this we will execute on those promising investment it's focused on what we hop.
Our next to take a Peterson JP Morgan.
Hey, thanks.
A couple here, but first I'd tell me I'm wondering if you can comment on the CEO search.
Area, where you are in the process timelines second on China I'm wondering if you can elaborate on the distributor order slowdown none of your peers.
Around Chinese hospitals, so how long do you expect that dynamic to last I know you talked about some recovery in the fourth quarter.
Third on alumina, you know, they're doing a lot of content deals you seem to be the only one hang them up front I'm curious why this right strategy and also when you made that decision and then lastly on guidance for Q guidance revenues below consensus EPS is in line is that all driven by the reorganization costs out and are you reaffirming long term.
Thank you.
Okay, Thanks, or I hope that I won't fall get in you know your points, but I think I took note. So the social does your first of what I don't want to speak on behalf of our chairman and I've, a bold, but as we said that the companies looking for a permanent CEO .
Which means that obviously internal and external candidates, we'd be very welcome to apply I expect this process, but to gain de Cesar bulk material for me to last probably around six months at the same time I'd. The woman their results. He joined the company. There is an executive team. There is a very good she now she's taking 10.
Them between cheery myself and all and we are here to see other company for the coming month and.
And moving it into 2020.
China or what is happening or what we have seen.
Is that.
Hosts be towards them.
Hi, probably.
Increase them their terms of payments.
Sure well, we're coming off shore distributors.
Basically we have been impacted by <unk>, because I was just kind of oh speed over effect.
Then faced with those longer terms of payments.
Distributors I've read use their all those.
Two catching.
So do you see is what happened.
I immediately went to China, you made your T. challenged the team locally to take stronger commercial elections in the money touring overwhelm commercial partners and I visited almost almost be towards we taught telling me that that situation should note last four very much stronger riser kind of a hiccup.
However.
To be fully transparent I believed that the molecular diagnostic market, which was probably say to be growing above 20% in China in the last year as probably know slowed down between 10% to 15% that these are reasonable expectation for this market and do you see is why don't you.
Seats that form each sign I used to key for.
Got you had gen because.
Musket of that size.
I remember a I remind everybody that the size of the market, China is probably around $2 billion asphalt diagnostic market of that size.
That does keep growing at a healthy double digit asked you to vary over you see interesting.
Yeah, Let me now I'm not sure that <unk> are completely got your questions. So if you if I'm not hearing millions. So please come back to me.
Yes, there are oh.
A lot of owes they'll kind of partnerships with ER, we use a or by you do mean that we suppose or companies, but what I find the really interesting is that remember that K.U.S.N. how's that vision for LNG, yes, Oh sample to insight, we believe into value offering a full work flow from.
Reality color to that time that you see some that interpretation and and you see is why I've seen that does this partnership is very specific catch in specialty casualty and leadership is made on sample prep.
He's made on library prep.
He's made oh of chemistry.
And.
That time that he sees by your informatics and you didn't mean that trend is made of instruments.
Both for life science and for diagnostic.
So I hope that that time. So your question, but again, please come back to me here and for the last question I'm going to handle got to all.
Hi, Tightrope in term of God I would clearly says that for the fourth quarter does the guidance is as we said I'm very clearly at all to have to deal with the changes in our set up a one clinical ngs and therefore, the impact on the companion diagnostic side, but I think as to your just alluded to we see that was a is it.
Change in dealing with the or thought about putting us here as well as a timing impact because it's quite up till said, we had to stop certain development on the co development side. Nevertheless, I think it's very Louisiana to believes that there will be able to sign more agreements and again that you're going to at all to and 2020 revenues for us. So.
These are clearly something what is going to have them overtime as well.
On the other side profitability I think it's actually quite strong we shouldn't a again or to be due to negative on the topic as well, we see a nice spike or expected not spike or what's in the fourth quarter in terms of course Mars in terms of EBIT margin and at the end of a de I've seen school well for us in the fourth quarter, we actually feel ansys yet.
With the profitability, which is probably actually in line with a U.P.S. guidance even have given all the off this year. So I would say that is something about we should put in perspective as well for 2020 as a it gets way looting before us ball I think the see a couple of trends I also do believes that we had a reasons to do all.
It was talking about clinical efforts are what ngs, because we believe that doesn't illumina partnership is probably a strongest solution, bringing the strength of both company together and I would.
Be again, I'm not surprised if that should be on a mid to I'm not even the positive direction for us. Nevertheless, I want to be ought to be a qubec CLIA onset of till you said, we clearly I know a two quarters in a row well we unfortunately.
Missed our guidance as well and you should expect that be ticky, a a cautious view going forward as well and I think it's something what is important for us.
Thank you all and I think that could that I didn't really a catch or oak or catch. Your question. Initially so if I if I understand better so first of all.
I went that ER is jeter was signed I mean, we worked on that deal during the summer and we are basically close that deal and signed a deal.
At the end of a of the quarter very early October the she's when we announced a deal.
So your question when we had a or kind of access fee I think the beauty of that de lever that we have a complete access to all existing and future diagnosed <unk> platform and for DC, we paid the very modest amount.
To gain access to Jim's install base, so basically what I liking that d. It in that D. These two each one eats specialty we are very strong from sample prep to chemistry to that the interpretation. They are very strong interest from meant they shouldn't we bring both together and we have a winning solution for the clinical market.
Next I look at Evercore ISI.
Hey, guys couple of here one on TV and then one on the guide.
So I guess first on TV when you think about the ER the mid teens full year guidance, if that's still intact and and if so was the D.S.G. catalog contract baked into that guidance and coming into the Fourq. You could you guys had a pretty big step up there and then it for only can you kind of bridges for that for Q3 percent guide. So if you.
Look at it you have basically a 2% to 3% headwind from Cdx, you get a and if that TV guide is correct and my math, you're getting about 4%.
Benefit from that and then kind of stat, assuming you know 50 to 100 basis points from there, but that implies the rest of business only grown about a percentage point I'm just kind of.
Bridge the gap there to the to the full year and the Three Q4 q you got.
[noise].
So on on the on the TV question before or <unk> take seat.
Yes, it does it affect or did you find a for example, you referred to the GLG catalog, but also as affect those we believed that or 15% to basically a mid teens growth is perfectly or I will target for fourq. Once you feel on these factors many features.
These factors.
Or price pressure in some countries. It's it's factoring also do your rivaldo. Some competitors. Its factoring go so just trying to follow up bought for you and you know that we have that Oh very strong partnership with that yes. So information I think we algae first company on this I grew up a market to automate deal fell from.
Preeti to quote you backend solutions. So these factors all those they top 15% growth rate for the coming years, you specifically, what we need to have in mind.
Hello.
And to fall I think first of all and just in addition to about two years, just said have in mind that of course, it falls caught the auto loss here was a very strong TV business a girlfriend I think that's lost the fourth quarter last year was a 29% growth for it so that clearly I feel a policy certain baseline effect. Nevertheless, I think if you look on.
The overall franchise you should have in mind not not only as a companion diagnostic in fact, a on the Ngs side is it had been for us in the fourth quarter, we ought to clearly set that China on about inside is improving but I think we were also very straight forward in saying that it's not something what is going to cleared out in one quarter pulled it takes a few quote.
The small.
Given that and I'm.
And growth with a again, 3% in tool or two to sweep present headwinds from the companion diagnostic or not this strong overall, China improvement puts us for the rest of civil and a very reasonable we'll see five 6% Colvin sweat and I think that is probably the way to look at it.
And I would take it from me a there's no reason for us to be or what no overall business a in terms of guiding view other being about vision has under leveling and again caught up for quarter. They want to why the into what move into right direction.
Well go next to stop buying out at Ambac Bank.
Yeah. Thanks for taking my question I'm, especially I Wonder if you could just highlight please.
Why why the development panels for the cost have been delayed and also perhaps give us some discussion as to the progress of the news and anymore DXP and menu in the U.S., which I think he's quite central she'll push in decision. There. So if you could talk about studies place I'm more broadly I think.
Five months ago.
Yeah, the capital markets day, the company outlined.
9% topline growth double digit earnings growth and I think the basis of my understanding was a college and actually is currently and the structural portfolio. It's a 6% growth company in a few deliver some of these new drive as well. It takes you into that higher single digit category with some leverage now appreciate there's a lot of.
Moving parts you know some delays in menu termination of gene made up new collaborations and social [laughter], but what I would like to understand and is.
<unk>.
Framework of expectation still your expectations today that you can be if you execute well a high single digit quite as company or has something fundamentally changed in the last four or five months thinking.
So thanks for the question, so going first to carry us to kinda stuff I'm sorry on your money. So so.
I mean as you know I think a I spent a significant number of years in diagnostic and a.
Development activities.
In diagnostic.
Oh, I'm not always completely easy.
To forecast does you probably imagine we are living on the we are working on living organisms and have you see sometime we have he could you know development those he cubs could be a ER contamination issues all could be some organism.
Are showing easier. So unfortunately gets evolve sold for a opposed the cheap. So do you see explain basically that traditionally I always try to put the buffer on development timing, but let's be clear TP core development I mean, I V de Niro diagnostics sticks around three years four in U.S. It that's always what I'd say.
Right to factor and the closer you get to the market launch to the do sometime due to the the most surprising sometimes some some very last reserves.
So.
Do you see is until controller, yeah, a in borrowing that what about sort of nice I talk I just thought but do you see is why we prefer to.
Well, let's say.
First how to talk to fall Gonna Twentyfold those two assays each snow thing that she's questioning the quality of the okay. Yes that technology I can't do you find that Oh, no more delays I regret them or if you see a I would like to leaving the world. When there is no development delays, but here we have them yourself roughly let's say three to four month photos to us.
As.
We are already on good track because just to give you an example.
We are currently is starting to evaluate some research use only a a full my thought about where meningitis for Europe . So that shows you that we are very much I'd handover development.
Moving to do you mechanics.
The first thing that I would like to highlight is what's going on say the.
From seven assays to now with 10 are moving onto more assays in Twentys suites are going was a well, let's not forget that and you more Dixie still not a very large companies. So I think the performance of bringing to the market a 10, a C.E. coli <unk> assays is quite remarkable.
In the U.S., but.
Because obviously, we had to work out though they had to work out on the European clearance plus some claim extension for Europe . They are slightly late but let's not forget that one they already had been MTO say a approved sick and they are moving to more approval into 2020 Uh huh.
First and second hogs, especially what we called to five to 10-K assays approval.
And last but not at least it's one of D. A a few see stem that combine not only regulated assays, but also aided de tea and you might think says if they reach L.P.T. laboratory developed test menu.
Hi, Scott on your very general question on long term.
Trends for the company I think I always prefer to two onset of live in more detail and was a or give some insight into the framework to just let alone.
If you just to view of what happened over the last a few weeks I think it's they clear to seize that we changed our strategy of on clean he could ngs based upon the shape of Illumina and that clearly has an short term impact or oil revenue growth with but I as I said on indicating before.
It should be was a a mid to long term positive for us because your brings the strength of two companies together well bores are clear market leader into that area does specific area.
If you know look on the other girls drive us I, just can't see that too many things have changed or shutdown, but should have a change into mid term.
TB you had a very strong quarterly other very good here today performance and have in mind that Oh, a midterm to kick off for that business until 20 trying to see percent is a 10% a number and kill effected in order to probably upcoming events are on competition over that time period.
Sam is too for kind of starts you can clearly see that's a number of placements we had with no control. It turned out and then over there was no probably a tune up placements one of the Perclot, though it's good yeah, what we'd love to have certain panels are few weeks all the other laid out there's no question on said, but do we have and.
Dollops up we will see menu expansion not only next year, but what's the time behind I don't think so so yes, I would say on the on the midterm peer to 2023 chaos that should be on its way as well sammis normally x. I don't have to repeat what what are you. Just said the is clearly I would say a good placement strategy in your.
Go up going on menu expansion, so I would say, it's moving into right direction, but last but not at least a piece we called out all the sequencing strategy was mainly driven all its over the last couple of or actually caught us and probably the last two three years by a very successful univar the solution a part of that.
Isn't that clearly it's also reason why we're going to come films 180 million dollar target for this year for sequencing in general because there's a there's a good business Ross and I don't see any reason to believe southern incremental partnership you look like there should be a negative phosphorus that so we're not going to change come from or do.
And I are midterm guidance as of today, because we are working here from quarter to quarter I'll give you an 2020 guidance.
Again end of January early February and are again that as a basis for off or long term guns, but I think the trends really hasn't changed and be few that's the overall market in general, particularly in Europe and U.S. stable.
Well, there's next at Piper Jaffray.
Great. Thank you and good afternoon, everyone. A couple of questions. Jerry first a bigger picture picture question and then secondly in operational once a first philosophically can you expand on some of your comments about priorities at Qiagen I'm certainly we appreciate the increased attention at R&D, but does it also include a portfolio review and then.
Secondly, can you speak to the pharma and academic strengths in the quarter, perhaps calling out some trends in particular I and also just how sustainable are you thinking about that franchise.
And then roll and in terms of the aluminum partnership how should we think about the internal investment netting against the expected gene meter spend will it require additional investment or more or less than you were budgeting for the the ongoing investment in new iterations of gene reader. Thanks, guys.
So bill thanks for the question the I.
I'm not sure that I caught the second part for me, but but so to.
The first policies on the portfolio I mean, again, I repeat or like any company. We have to constantly are we view our portfolio location, but as I said before I really believe that if we combine to core activities of Caojing plant.
Plus the newer investment over the recent years Todd.
Remotely Ics and have won.
GPCR for life Science, we have everything in hand, now for the coming years, but do you see we continuously when you talk to make sure that we really invest and they insist on that we will invest where we really can't take leadership position D series D. C is key for me.
We cannot be everywhere, we can know taking the invest every weekend debuted our activities into too many activities, we ever Saudi portfolio from life science to Mdx to buy you informatics de she's what we have to two execute I think the second part of your question, but come back to me a a beat if I do not understand it.
Was wrong to strengthen the pharma business, especially for life science, it's basically to revise and as.
As a whole lot described it's basically driven by some very <unk>. Some very good growth continues to go from the a fast growing countries in the self of Europe , especially Italy, Spain and two okay.
We have and we continue to have.
Good reserves with KFC is when you see stem. So all these contribute to that sort of number.
[noise] going through the second part of your question. The once Illumina partnership I think is clearly a partnership we are going to invest into by the same time of course, we all know exactly had significant investments into all a next generation sequencing platform, which we discontinued.
And therefore, I wouldn't expect that yeah, it's any increase on the operational expense side for 2020. It will editors that I was a believes that a again also love investments as I say set us up probably game going now in two areas with not only a higher but probably ought to foster a turn away at that.
That is something but should help us to maintain and probably even improve all profitability next year or on a relative level quite quite nicely.
Well move next to Daniel Wendorff Commerce, Spain.
Yes, hi, and thanks for taking my questions and two if I may and one that's related to kind of statistics and again.
And I said, you gave us the the number of placements and 800, so far and yet still you only achieved 11 million euros to lessen say as opposed to 15 million expected can you potentially.
Explain where the difference if that's your return expectation has its just the the delay in the launch of the new penalty anymore color. You can provide that would be helpful. And then obviously what this means for your full year number I'll kind of stuff to X. I think he would drop through internal expectation was for a $13 million.
And second question if on the companion diagnostics the drop in revenues. It can you. Please explain the background off that 37% drop again in Q3 and why that it's a week in Q4 and how should we think about this going into the first half of 2020. Thank you.
Thanks for the question. So yes, you are perfectly right. We are our below our expectation on cat, yes that.
However, as we highlighted we are extremely pleased with genes Freeman said I mean, if we compare I was says we use Angie insisting on says performance over the leader on the market, a which is probably putting something like 200 and use them for a quarter. We are exactly at the same pace now so for a company that does.
Let's move on you.
I think it's a good performance why yeah, we or later on consumable that's a very very significant to peak of attention for me.
First of all there has been some delays we were slightly delayed you know were respi right to read or clearance 80, a key runs in the U.S. So to some extent we missed the flu season over last year, because if you remember we came in Q2 of two falls and then and Nitin first.
Second because as I said before.
We were expecting to our Gee I needed for the U.S. clear of the by Q4, so she's not going to happen and seeking to be very honest with you I as I said I prefer to be.
Cody optimistically, koshers or we yes, realistically ambitious, but we are coming though we Scott yes, that's in the U.S. to our first flu season.
And I want to make sure that we are delivering and executive team before to get a ticking or stronger assumption. We all know anything as a as we go to a certain extent. So do you see is why I believe that yes, we we'd be a below our were 13 million original expectation for the year I beat.
You have to be around 14 to 15 million. That's I think he is achievable compared to where we all know or.
For the companion diagnostic and again.
I don't want you make it too complicated, but what we have to keep in mind.
He is that de she's clearing activity were catching our leadership position in the world probably the largest number of pharma partnership among all deals are companies and it's made or it was made primarily for many years of PCR based deals.
But it does you all know over the last the last especially four to five years or pharma companies up you know so eager to work on Ngs based technologies for those companion diagnostic.
And we were having last year.
Revenues coming from de Brookman coming from our own Ngs platform, we found out that I'm not going to happen now as we stop those development, we expect to progressively trends filled those development engineers base to do you mean that partnership but over you see we need.
To be very clear de she's going to take could be tough time, because we need to develop the keep saying we need of your speech. We agree on those keeps with our pharma partners. So you will see a progressive ramp up not into first half of the year progressively much more towards the end of two falls on Mtwenty, but that you speak <unk>.
Yeah, it's used to getting the PCR based off our companion diagnostic is still very heavy that's the core base that we want you will continue to defend.
And just to fill up you ever so there's some some some numbers because I clearly here that's a companion Tropic isn't important one for you.
Having mine and I know that you have said somewhere in your dogs that a 2018 was clearly a very strong companion yet for US. We ended the year was at 58 million dollar business, which was calling for 28 in his 34% go for it and I think we've all this very clear to say that there's a volatile businesses into one inside and that is clearly a go.
But you shouldn't take forward as well.
Well, if you look into saw them false Claude you see actually a couple of impacts here coming together sort quoted <unk>. We just said the is it for you talked about that in the summer. There's a 4 million negative impact from Oh on companion diagnostic autopsy or cancellation opposite joint venture the some action.
For the fourth quarter. We also have for all of the same reason we have also on the bought three to 4 million impact to the negative or all of this joint venture cancellation, but incrementally oh until we have for wallet or probably somewhere between eight and 10 million U.S. dollars of impact did include senza ngs context or does it seem to.
You just described in detail, that's clearly a a headwind which is keeping us busy and I think this number should help you to get your more links to it.
Well go next to Dan Brandon at U.P.S.
Great had it maybe a bit of a different question hygiene doesn't breakout the growth for your core DNA kit business, rather flows through different segment lines that said I mean.
This business could arguably one of the most potentially attractive products within cadence. So I'm just wondering.
Is this something that you can provide some color on about what that kit business has grown out over the last few years, you know we calculate the growth could be pretty modest you know what the outlook in the competitive dynamics are and whether or not that businesses.
Receiving the adequate R&D in general sport.
Yeah, I would say that underlying base business facade for prep is probably something on three plus percent on a constant exchange, but it's a solid business one off costs that we see all through the with it was a modest positive trend or two to.
Mid along to because what is what is being helpful is clearly the kinda symphony placements and that is clearly used more malls. So as a sample prep machine in front of many different solutions. A of course it is very important for them close to see if all hot because it is a high margin business for us and I think that is something.
We feel very good about again every quarter I see a cause symphony placement number I I think is a nice continuation of an important business was.
I would like to a or in seems to have an highlights what or the only thing is that those placement of KFC. If when you are moving very well and sometime you might see you an evolution.
In the revenue recognition because we place most sees them that we said it sometime because he sees what the market is is are willing to accept but but what is important used to have to seize them at customer sites and generating revenues as a a soon I suppose seaborne because that's what on said, it's a very healthy margin for the company.
Well its next to Jack Meehan with Barclays.
Thank you a good morning, good afternoon.
I've two questions on one on gene reader and one on a digital PCR.
Virgina reader I was wondering if you could just quantify for us within the 180 million dollar target how much is related to gene reader instruments and consumables and <unk>.
I was wondering if you just give me some color on what the customer reaction has been to the decision to not invest in new instruments. How do you think the generator revenue contribution is going to trend from here.
And then.
ER on digital PCR just curious if you give us some updates in terms of the timeline there in terms of when you plan to get introduced the new integrated box.
Very good things for the question Jinri. Their overall these are out of the numbers that we are these clothes for Ngls. She is roughly around 5% of that total revenues.
Or so so customers reaction and I've been a quite positive because this you're getting those trends and interest over the partnership between those two leaders full day more choice means also a a program <unk> a a full access to not only usually the.
If you mean that platform, but the full set of solution that fully integrated work flow.
But I honestly I believe that that that you didn't retail sales we'd program progressively decrease over time.
There is also a marketing solution for this the markets. He is asking for more and more for larger and larger partners rather than targeted panels. So as we said we maintain the we continue to see if he sent to serve those installed genie retail customers, but I expect them to progressively or wind down the overall 2020 and.
21, but we continue to salvage them.
GPCR as I said before you see I mean that are forecasting a development time, he's always tricky, but we expect this system to be launching the second half of two falls on then 20 and so far we are on track to respect that commitment.
And that completes the question answer session. Please continue with any other place you missionary.
Yes. Thank you operator, its jungle RT and thank you have to all of you for your participation. If you have any questions or comments. Please don't hesitate to give us call bye bye.
Ladies and gentlemen, this concludes the conference call. Thank you for joining and have a pleasant day bye.
Oh.